{"name":"iTeos Therapeutics, Inc.","slug":"iteos","ticker":"ITOS","exchange":"NASDAQ","domain":"iteostherapeutics.com","description":"iTeos Therapeutics, Inc. (ITOS) is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company's pipeline includes several promising candidates, including infigratinib and domvanalimab. iTeos Therapeutics is a relatively small player in the immuno-oncology space, but its research and development efforts have garnered significant attention from investors and the scientific community.","hq":"Waterloo, Belgium / Cambridge, MA","founded":0,"employees":"","ceo":"Michel Detheux","sector":"Immuno-Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$700M","metrics":{"revenue":175000000,"revenueGrowth":177.9,"grossMargin":0,"rdSpend":145447000,"netIncome":-134414000,"cash":142131000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"infigratinib patent cliff ($0.0B at risk)","drug":"infigratinib","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"domvanalimab patent cliff ($0.0B at risk)","drug":"domvanalimab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"iTeos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"iTeos Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and financial performance.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"iTeos Therapeutics Announces Collaboration with Gilead Sciences to Develop Cancer Immunotherapies","summary":"iTeos Therapeutics entered into a collaboration with Gilead Sciences to develop and commercialize several cancer immunotherapies, expanding its pipeline and increasing its global reach.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"iTeos Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of Infigratinib in Patients with Advanced Solid Tumors","summary":"iTeos Therapeutics reported positive interim results from a Phase 1b/2 clinical trial of infigratinib in patients with advanced solid tumors, demonstrating promising efficacy and safety.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdzY5ZGdsTmNkSWFsVHNMcm5odGNYMHlGWnRVY1ZRck9VbGl1cHE2bUVVcW5sYjBFZzlnb1RJeDlOckUxQUlKQ0dSank0WVpObk5VQUw2NW9kN2NzdDhRelVGcURGMkFIWHRMejFVQ0hFaU5rTWZVWkVDMDJ2bm9mMElpbW5ZeHdJQVBOWDdLdHBxRTh1YUdzMDMtY0Z4MWpyNkx5RERiS1hhaGFzM2RicUVHN2d3QnVJS3JGLTNKbElNd1E?oc=5","date":"2026-01-05","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About iTeos Therapeutics (ITOS): Underdog Stock or Next Big Biotech Flex? - AD HOC NEWS","headline":"The Truth About iTeos Therapeutics (ITOS): Underdog Stock or Next Big Biotech Flex?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNF8yRVVRdmFIVnN4aUFZOXpLSzhrUU1nZE1Wd241MllMMldSMVROMmduVHJKa1lEZS1kMFQ3MTIzcXhBTVVOR1RCSGZWRk1ZMXFraTRZTmNYODc1dEY4VGdUelUxM0pnWWVwd09LaHpOd0xOUGd3OWZ4eV9JODNWYnVUd1ZkMkZleGd3?oc=5","date":"2025-12-31","type":"pipeline","source":"The Business Journals","summary":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals","headline":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBrU0pwZWwzR2QxcXRpUEU0UEhIZzVsUUNWS2pSSWxxY25VQVd6enNmdDVzM091d1l0cmZTZ2dIMmNxWGUyV3d4Tk1feVQ0TndYY3UzYXpxa0lSN0Q2b0dVZ09mcHZHY1dKNnk4LThod3VYWENwVDU4?oc=5","date":"2025-10-31","type":"pipeline","source":"Fierce Biotech","summary":"The 2025 Biotech Graveyard - Fierce Biotech","headline":"The 2025 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQYl93T1VPVk55TkUyeWd2eklPaFZiVm1rV2l1LVZ4SFdsQjhNeHNvdXQ4Ml9aY2FrVnNPUG1wYjdzSFEwR2paUGJ0Z0U5NVRDZ1hyVUYxZVlQUlkyRmhoN0R1SGhrYkRSbVBYZ2phNlBfUXc5MUpmMkQwalNmQUlraFpzanNITk5hczlPMnpNOVVHUURERlh0LTFqTDE0SDBDWXVVeFdXNTBQMXJhUkpJ?oc=5","date":"2025-07-30","type":"pipeline","source":"BioSpace","summary":"GSK to Inject ‘Tens of Billions’ in US Amid Trump’s Tariffs, Pipeline Reshuffles - BioSpace","headline":"GSK to Inject ‘Tens of Billions’ in US Amid Trump’s Tariffs, Pipeline Reshuffles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNeWNxS292cFJ2U3NZUi1LMTVNblNDYm9yMkdsc1JJYzNWOWwwX1BhNlYwcFBReXNLRC1STk96RTdxUjJrLVQyRFZzSktrdGVBbFVqQVRWcm1lVnJQN3VCUk5UZEFTY3lBYW5lZnlNX3RUTWI3Y0NHR1dtWGY3Tld0am8wVjBiUmpwb2FPcUZjWHNiVHBhOTV6TXVUYkdKTkhidlpMWnNyUQ?oc=5","date":"2025-07-21","type":"deal","source":"Fierce Biotech","summary":"iTeos, reeling from TIGIT fail, becomes latest prize for deal-hungry Concentra - Fierce Biotech","headline":"iTeos, reeling from TIGIT fail, becomes latest prize for deal-hungry Concentra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxNOGpsY0pRUk9TYlZiakUwWTRRVkg3S251bUhxZUpGUGRqOEFhc1J2S05wc2xhNlllSExTRXhBbklVcXR6aHV2dnlyZ09qX2lwODFnWHF5amNNN095RUZQbFVvMU0wQ0I0T1E1bkhST1Uydy1jajAwY2c3SDY5U0FVSERpQmJfMHhQTnZvNkU2V3JmcG9IaVV2TnRlbE9WQVBKbjdpNmEzSjh2N0ZLeWJmMjhSazZBU0l5TWx3Q01ReHBBOEg1R1lla3NpX1NxdHlFaWNKVl9Ua3E0MWU4TjlNR3d2cGtIaF92d0hYUHVxTXhibW1HTXExWTBfOUtjdHlNU3hiYTZsWWVlT196R3RDbFZkUXJNR1BoaTVLSHZpVkt1RmF1RGZEQmk0ZHMyWFYzN1VWSERR?oc=5","date":"2025-07-21","type":"deal","source":"GlobeNewswire","summary":"iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire","headline":"iTeos Therapeutics Enters into Agreement to Be Acquired by","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNeHh2NEpvckYza29kdGs3amRCdmlWT0tmXzFWcHd4TmNleFlTRmxuTDltUm1BRnZLSHR6d3V5cklCNHYyVER4Q2hDOGxUTVhUU2lZVGJucmV1Wm4ydmE2SUdWTkJ1RWNyZnZUYWpTNVZId0pBN2p3Z1BsLVVENFBoOUFzbw?oc=5","date":"2025-06-20","type":"trial","source":"Oncology Pipeline","summary":"Opinion: dealing with failure, iTeos style | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Opinion: dealing with failure, iTeos style | ApexOnco - Clinical Trials news and analysis","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOcjZ5MnlnM21sQnZqdS1nZVRSSjJ1T0JJdElqcHhjYnFWQ2dvMmhYVVU0anJNQ0xuWXl1aUU0WDZoX1lGSEVjajNmajRXTE5CR25BS1FlY2RwV2dqeWYyczNZSjlyUDQ1cHVkQXVwdl9SR1hoRWYwU3ZHNTZlNTNjN0U2QXpXclVkakhtU2gxaVlSQVZ4RXJxM0VuS1R6RHN0U2ZtUGRzOE05OW13UzBGQnJ2UXFZekhISUE?oc=5","date":"2025-05-29","type":"pipeline","source":"statnews.com","summary":"Post-TIGIT flop, iTeos Therapeutics is shuttering - statnews.com","headline":"Post-TIGIT flop, iTeos Therapeutics is shuttering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWlV3eDJoenFBblgyanNpTVlfRVJXSjhJemJqS2ZIVUxPd0lWTEtCZGN5eDVLTTZUaENzUFJkMk5STTA0X3BzbjR1Ukl6RXhTeXRXbndmbUZ6d2JFT3JDQzYycHF6aXkwSG9UTEtzUVlsalk1eXFfU212TEhBUjUyQVFHS1JWQjFNVTBlVjBwTG1yWGVv?oc=5","date":"2025-05-28","type":"pipeline","source":"BioPharma Dive","summary":"Cancer drugmaker iTeos to shut down - BioPharma Dive","headline":"Cancer drugmaker iTeos to shut down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQbEZVOEluc3lmb09NVHVCMUhXcEg1WlFsbC1OSU5OSzgtUlYySFF0aEJzU01ZX2JZNUhWRDluN1FQdlR4Skl1WmJRa0tBYzNoaDZ0MzRfUmpfRjhpQmIwLVRVWTV2ci1rXzh1dFlEZzFXdzhxUGRVUDNNSlR4Um1LYnV4N1lCQWd4cVExTFlwcGFxQ3d6OFhfc2JjMVJPeTE5UTl5WjBiejJGRFNCMkNBeU1aMFlmLXhtUHJsUEw4OXFfNWkyaWVzQ3BYN1U2VFNSUzhzaw?oc=5","date":"2025-05-28","type":"pipeline","source":"GlobeNewswire","summary":"iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewswire","headline":"iTeos Therapeutics Announces Its Intention to Wind Down Operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE85WUtDdWt5Vk9QYkM1QkFkU1VVTWs5NU40ZVAwbWRhWU8tSkI4bk41LXFUYkZLNGxUX0dzNTNSaW91d0RaV0I5RVpvWkFVeEN3WFlzQkFhVGZYV2FSMGFrUFZCbGVURi1HS0ZocWJyWTU1ck1OYWl3bA?oc=5","date":"2025-05-15","type":"deal","source":"Yahoo Finance","summary":"GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance","headline":"GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE03V1I2c2NCemRrMzFzVWpJdjZIYWZkbEVEQldacnR2b0NwTkRZbFI3M2t3S1I1bDRRSUExLTVQWXRGWU04VEpUZjRjZHlGc1ZwSWRr?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ERAS Stock Price, News & Analysis - Stock Titan","headline":"ERAS Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"infigratinib","drugSlug":"infigratinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"domvanalimab","drugSlug":"domvanalimab","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immunotherapy","Oncology"],"financials":{"source":"sec_edgar","revenue":35000000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":35000000,"period":"2024-12-31"},{"value":12595000,"period":"2023-12-31"},{"value":267630000,"period":"2022-12-31"},{"value":344775000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":145447000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-134414000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":142131000,"cashHistory":[],"totalAssets":686976000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}